RecruitingPTSD
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
Eligible age
19–70 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
Sponsor: White River Junction Veterans Affairs Medical Center
You may qualify if…
- ✓ 1. Age 19-70 years
- ✓ 2. Weight ≥ 45 kg
- ✓ 3. Diagnosed with PTSD as determined by the CAPS-5 within seven days of enrollment
- ✓ 4. Eligible for Veterans Affairs healthcare
- ✓ 5. If person with childbearing potential, use of acceptable method of birth control (i.e., effective contraceptives, abstinence) is required.
- ✓ 6. Able to read, understand, and sign the informed consent document.
- ✓ Exclusion (unable to participate) Criteria:
- ✓ 1. Pregnant or lactating person
Where it's recruiting
Vermont
White River Junction
Source: ClinicalTrials.gov · NCT05637879 · last updated 2025-04-24